TB Alliance: Lancet Article Highlights Hope in the Tuberculosis Drug Development Pipeline
5/19/2010 9:52:34 AM
NEW YORK--(BUSINESS WIRE)--According to a paper published today in the Lancet, there is unprecedented progress in the development of the global tuberculosis (TB) drug pipeline with 10 drug candidates currently in clinical development. The paper was written by a team of renowned international experts led by Zhenkun Ma, Ph.D., Chief Scientific Officer for the TB Alliance, a not-for-profit organization accelerating the discovery and development of new TB drugs. The article, published as part of the Lancet’s Series on Tuberculosis, also highlights the significant funding and other challenges associated with the pursuit of life-saving treatment for the nearly 2 million people who die each year from TB.
comments powered by